Role of C-Reactive Protein and Erythrocyte Sedimentation Rate in the Diagnosis and Monitoring of Treatment Response in Treatment Naïve Subjects with Chronic Pulmonary Aspergillosis.
CCPA
CPA
CRP
Chronic aspergillosis
ESR
Inflammatory markers
Journal
Mycopathologia
ISSN: 1573-0832
Titre abrégé: Mycopathologia
Pays: Netherlands
ID NLM: 7505689
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
received:
20
03
2023
accepted:
29
05
2023
pubmed:
8
8
2023
medline:
8
8
2023
entrez:
7
8
2023
Statut:
ppublish
Résumé
The role of C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) for diagnosing chronic pulmonary aspergillosis (CPA) remains unknown. Herein, we investigate the diagnostic performance of serum ESR and CRP in CPA. We retrospectively analyzed the data of treatment-naïve subjects with CPA and diseased controls (post-tuberculosis lung disease on CT thorax). We treated CPA subjects with six months of oral itraconazole. Our primary objective was to evaluate the sensitivity and specificity of ESR and CRP in diagnosing CPA. The key secondary objective was to study the change in the inflammatory markers with treatment. We included 434 subjects and 20 diseased controls. The sensitivity and specificity of ESR (n = 434) and CRP (at cut-off value of 10 mg/L, n = 308) in diagnosing CPA were 42.9% and 65%, and 52.3% and 65%, respectively. Both ESR and CRP had erratic trend following treatment. ESR and CRP declined or remained stable in approximately 60% of subjects but increased in approximately 40% of the subjects despite treatment. Serum CRP and ESR have limited utility in diagnosing and following subjects with CPA.
Identifiants
pubmed: 37550433
doi: 10.1007/s11046-023-00756-8
pii: 10.1007/s11046-023-00756-8
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
705-711Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Nature B.V.
Références
Sehgal IS, Dhooria S, Muthu V, Prasad KT, Agarwal R. An overview of the available treatments for chronic cavitary pulmonary aspergillosis. Expert Rev Respir Med. 2020;14(7):715–27. https://doi.org/10.1080/17476348.2020.1750956 .
doi: 10.1080/17476348.2020.1750956
pubmed: 32249630
Denning DW, Riniotis K, Dobrashian R, Sambatakou H. Chronic cavitary and fibrosing pulmonary and pleural aspergillosis: case series, proposed nomenclature change, and review. Clin Infect Dis. 2003;37(Suppl 3):S265–80. https://doi.org/10.1086/376526 .
doi: 10.1086/376526
pubmed: 12975754
Black S, Kushner I, Samols D. C-reactive protein. J Biol Chem. 2004;279(47):48487–90. https://doi.org/10.1074/jbc.R400025200 .
doi: 10.1074/jbc.R400025200
pubmed: 15337754
Fincher RM, Page MI. Clinical significance of extreme elevation of the erythrocyte sedimentation rate. Arch Intern Med. 1986;146(8):1581–3.
doi: 10.1001/archinte.1986.00360200151024
pubmed: 3729639
Bray C, Bell LN, Liang H, Haykal R, Kaiksow F, Mazza JJ, et al. Erythrocyte sedimentation rate and C-reactive protein measurements and their relevance in clinical medicine. WMJ. 2016;115(6):317–21.
pubmed: 29094869
Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest. 2003;111(12):1805–12. https://doi.org/10.1172/jci18921 .
doi: 10.1172/jci18921
pubmed: 12813013
pmcid: 161431
Schweer KE, Bangard C, Hekmat K, Cornely OA. Chronic pulmonary aspergillosis. Mycoses. 2014;57(5):257–70. https://doi.org/10.1111/myc.12152 .
doi: 10.1111/myc.12152
pubmed: 24299422
Godet C, Philippe B, Laurent F, Cadranel J. Chronic pulmonary aspergillosis: an update on diagnosis and treatment. Respiration. 2014;88(2):162–74. https://doi.org/10.1159/000362674 .
doi: 10.1159/000362674
pubmed: 24943102
Maghrabi F, Denning DW. The management of chronic pulmonary aspergillosis: The UK national aspergillosis centre approach. Curr Fungal Infect Rep. 2017;11(4):242–51. https://doi.org/10.1007/s12281-017-0304-7 .
doi: 10.1007/s12281-017-0304-7
pubmed: 29213345
pmcid: 5705730
Sehgal IS, Dhooria S, Choudhary H, Aggarwal AN, Garg M, Chakrabarti A, et al. Monitoring treatment response in chronic pulmonary aspergillosis: role of clinical, spirometric and immunological markers. Clin Microbiol Infect. 2019;25(9):1157. https://doi.org/10.1016/j.cmi.2019.01.007 .
doi: 10.1016/j.cmi.2019.01.007
Sehgal IS, Dhooria S, Choudhary H, Aggarwal AN, Garg M, Chakrabarti A, et al. Efficiency of a fumigatus-specific IgG and galactomannan testing in the diagnosis of simple aspergilloma. Mycoses. 2019;62(12):1108–15. https://doi.org/10.1111/myc.12987 .
doi: 10.1111/myc.12987
pubmed: 31408547
Sehgal IS, Dhooria S, Choudhary H, Aggarwal AN, Garg M, Chakrabarti A, et al. Utility of serum and bronchoalveolar lavage fluid galactomannan in diagnosis of chronic pulmonary aspergillosis. J Clin Microbiol. 2019. https://doi.org/10.1128/JCM.01821-18 .
doi: 10.1128/JCM.01821-18
pubmed: 30626661
pmcid: 6425183
Sehgal IS, Choudhary H, Dhooria S, Aggarwal AN, Garg M, Chakrabarti A, et al. Is There an overlap in immune response between allergic bronchopulmonary and chronic pulmonary aspergillosis? J Allergy Clin Immunol Pract. 2019;7(3):969–74. https://doi.org/10.1016/j.jaip.2018.08.034 .
doi: 10.1016/j.jaip.2018.08.034
pubmed: 30205191
Sehgal IS, Choudhary H, Dhooria S, Aggarwal AN, Garg M, Chakrabarti A, et al. Diagnostic cut-off of Aspergillus fumigatus-specific IgG in the diagnosis of chronic pulmonary aspergillosis. Mycoses. 2018;61(10):770–6. https://doi.org/10.1111/myc.12815 .
doi: 10.1111/myc.12815
pubmed: 29920796
Sehgal IS, Dhooria S, Muthu V, Prasad KT, Aggarwal AN, Chakrabarti A, et al. Efficacy of 12-months oral itraconazole versus 6-months oral itraconazole to prevent relapses of chronic pulmonary aspergillosis: an open-label, randomised controlled trial in India. Lancet Infect Dis. 2022;22(7):1052–61. https://doi.org/10.1016/s1473-3099(22)00057-3 .
doi: 10.1016/s1473-3099(22)00057-3
pubmed: 35429465
Miller A, Green M, Robinson D. Simple rule for calculating normal erythrocyte sedimentation rate. Br Med J (Clin Res Ed). 1983;286(6361):266. https://doi.org/10.1136/bmj.286.6361.266 .
doi: 10.1136/bmj.286.6361.266
pubmed: 6402065
Kushner I, Samols D, Magrey M. A unifying biologic explanation for “high-sensitivity” C-reactive protein and “low-grade” inflammation. Arthritis Care Res (Hoboken). 2010;62(4):442–6. https://doi.org/10.1002/acr.20052 .
doi: 10.1002/acr.20052
pubmed: 20391496
Jhun BW, Jeon K, Eom JS, Lee JH, Suh GY, Kwon OJ, et al. Clinical characteristics and treatment outcomes of chronic pulmonary aspergillosis. Med Mycol. 2013;51(8):811–7. https://doi.org/10.3109/13693786.2013.806826 .
doi: 10.3109/13693786.2013.806826
pubmed: 23834282
Felton TW, Baxter C, Moore CB, Roberts SA, Hope WW, Denning DW. Efficacy and safety of posaconazole for chronic pulmonary aspergillosis. Clin Infect Dis. 2010;51(12):1383–91. https://doi.org/10.1086/657306 .
doi: 10.1086/657306
pubmed: 21054179
Nam HS, Jeon K, Um SW, Suh GY, Chung MP, Kim H, et al. Clinical characteristics and treatment outcomes of chronic necrotizing pulmonary aspergillosis: a review of 43 cases. Int J Infect Dis. 2010;14(6):e479–82. https://doi.org/10.1016/j.ijid.2009.07.011 .
doi: 10.1016/j.ijid.2009.07.011
pubmed: 19910234
Jain LR, Denning DW. The efficacy and tolerability of voriconazole in the treatment of chronic cavitary pulmonary aspergillosis. J Infect. 2006;52(5):e133–7. https://doi.org/10.1016/j.jinf.2005.08.022 .
doi: 10.1016/j.jinf.2005.08.022
pubmed: 16427702
Tochigi N, Ishiwatari T, Okubo Y, Ando T, Shinozaki M, Aki K, et al. Histological study of chronic pulmonary aspergillosis. Diagn Pathol. 2015;10:153. https://doi.org/10.1186/s13000-015-0388-8 .
doi: 10.1186/s13000-015-0388-8
pubmed: 26334307
pmcid: 4558778
Huang SF, Huang CC, Chou KT, Chan YJ, Yang YY, Wang FD. Chronic pulmonary aspergillosis: disease severity using image analysis and correlation with systemic proinflammation and predictors of clinical outcome. J Fungi (Basel). 2021. https://doi.org/10.3390/jof7100842 .
doi: 10.3390/jof7100842
pubmed: 35049949
pmcid: 8624268
Osborne W, Fernandes M, Brooks S, Grist E, Sayer C, Hansell DM, et al. Pulsed echinocandin therapy in azole intolerant or multiresistant chronic pulmonary aspergillosis: a retrospective review at a UK tertiary centre. Clin Respir J. 2020. https://doi.org/10.1111/crj.13171 .
doi: 10.1111/crj.13171
pubmed: 32077238
Kohno S, Izumikawa K, Ogawa K, Kurashima A, Okimoto N, Suzuki K, et al. Intravenous liposomal amphotericin B versus voriconazole for chronic pulmonary aspergillosis: a multicenter trial in Japan. Acta Med Nagasaki. 2018;61(4):167–76.